Céline Colacios

Identifiants chercheurs

IdHAL :

celine-colacios

ORCID :

0000-0002-7509-0675

Publications

Article dans une revue (19)

The Phospholipid Bis(monoacylglycero)Phosphate Confers Antitumour Immunogenicity to Exosomes Secreted by Dendrogenin A, Which Activates Its Biosynthesis in Tumour Cells Julio Buñay,Michel Record,Philippe de Medina,Silia Ayadi,Laly Pucheuet al. Journal of Extracellular Vesicles, 2026, 15 (2), pp.e70225. ⟨10.1002/jev2.70225⟩ Article dans une revue inserm-05495718v1
TNF signature in advanced melanoma patients treated with immune checkpoint inhibitors: Results from the MELANFα clinical study Mathieu Virazels,Amélie Lusque,Stéphanie Brayer,Matthieu Genais,Carine Dufauet al. International Journal of Cancer, 2025, ⟨10.1002/ijc.35416⟩ Article dans une revue (data paper) hal-04996473v1
Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti–PD-1 Therapy Efficacy Anne Montfort,Florie Bertrand,Julia Rochotte,Julia Gilhodes,Thomas Filleronet al. Cancer Immunology Research, 2021, 9 (5), pp.568-582. ⟨10.1158/2326-6066.CIR-20-0342⟩ Article dans une revue inserm-03402255v1
Thrombospondin-1 Silencing Improves Lymphocyte Infiltration in Tumors and Response to Anti-PD-1 in Triple-Negative Breast Cancer Elie Marcheteau,Thomas Farge,Michaël Pérès,Guillaume Labrousse,Julie Tenetet al. Cancers, 2021, 13 (16), pp.4059. ⟨10.3390/cancers13164059⟩ Article dans une revue inserm-04971585v1
Combining TNF blockade with immune checkpoint inhibitors in patients with cancer Anne Montfort,Mathieu Virazels,Céline Colacios,Nicolas Meyer,Bruno Ségui Nature Reviews Rheumatology, 2021, 17 (9), pp.577-577. ⟨10.1038/s41584-021-00653-8⟩ Article dans une revue (article de synthèse) hal-04960542v1
Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1 Caroline Imbert,Anne Montfort,Marine Fraisse,Elie Marcheteau,Julia Gilhodeset al. Nature Communications, 2020, 11 (1), pp.437. ⟨10.1038/s41467-019-14218-7⟩ Article dans une revue inserm-02492179v1
The TNF Paradox in Cancer Progression and Immunotherapy Anne Montfort,Céline Colacios,Thierry Levade,Nathalie Andrieu-Abadie,Nicolas Meyeret al. Frontiers in Immunology, 2019, 10, pp.1818. ⟨10.3389/fimmu.2019.01818⟩ Article dans une revue inserm-04905614v1
Sphingomyelin Synthase 1 (SMS1) Downregulation Is Associated With Sphingolipid Reprogramming and a Worse Prognosis in Melanoma Fatima Bilal,Anne Montfort,Julia Gilhodes,Virginie Garcia,Joelle Riondet al. Frontiers in Pharmacology, 2019, 10, pp.443. ⟨10.3389/fphar.2019.00443⟩ Article dans une revue hal-02332278v1
A Natural Variant of the Signaling Molecule Vav1 Enhances Susceptibility to Myasthenia Gravis and Influences the T Cell Receptor Repertoire Isabelle Bernard,Antoine Sacquin,Sahar Kassem,Mehdi Benamar,Celine Colacioset al. Frontiers in Immunology, 2018, 9, pp.2399. ⟨10.3389/fimmu.2018.02399⟩ Article dans une revue inserm-02439866v1
The costimulatory molecule CD226 signals through VAV1 to amplify TCR signals and promote IL-17 production by CD4(+) T cells Guillaume Gaud,Romain Roncagalli,Karima Chaoui,Isabelle Bernard-Cadenat,Julien Familiadeset al. Science Signaling, 2018, 11 (538), ⟨10.1126/scisignal.aar3083⟩ Article dans une revue hal-02117993v1
The costimulatory molecule CD226 signals through VAV1 to amplify TCR signals and promote IL-17 production by CD4 + T cells Guillaume Gaud,Romain Roncagalli,Karima Chaoui,Isabelle Bernard,Julien Familiadeset al. Science Signaling, 2018, 11 (538), pp.eaar3083. ⟨10.1126/scisignal.aar3083⟩ Article dans une revue inserm-04284289v1
TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma Florie Bertrand,Anne Montfort,Elie Marcheteau,Caroline Imbert,Julia Gilhodeset al. Nature Communications, 2017, 8 (1), pp.2256. ⟨10.1038/s41467-017-02358-7⟩ Article dans une revue inserm-04905428v1
TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma Florie Bertrand,Anne Montfort,Elie Marcheteau,Caroline Imbert,Julia Gilhodeset al. Nature Communications, 2017, 8 (1), ⟨10.1038/s41467-017-02358-7⟩ Article dans une revue hal-04866756v1
A Natural Variant of the T Cell Receptor-Signaling Molecule Vav1 Reduces Both Effector T Cell Functions and Susceptibility to Neuroinflammation Sahar Kassem,Guillaume Gaud,Isabelle Bernard-Cadenat,Mehdi Benamar,Anne S. Dejeanet al. PLoS Genetics, 2016, 12 (7), ⟨10.1371/journal.pgen.1006185⟩ Article dans une revue hal-01438135v1
A spontaneous mutation of the rat Themis gene leads to impaired function of regulatory T cells linked to inflammatory bowel disease. Marianne Chabod,Christophe Pedros,Lucille Lamouroux,Céline Colacios,Isabelle Bernard-Cadenatet al. PLoS Genetics, 2012, 8 (1), pp.e1002461. ⟨10.1371/journal.pgen.1002461⟩ Article dans une revue hal-02650348v1
A Spontaneous Mutation of the Rat Themis Gene Leads to Impaired Function of Regulatory T Cells Linked to Inflammatory Bowel Disease Marianne Chabod,Christophe Pedros,Lucille Lamouroux,Céline Colacios,Isabelle Bernardet al. PLoS Genetics, 2012, 8 (1), pp.e1002461. ⟨10.1371/journal.pgen.1002461⟩ Article dans une revue inserm-04284166v1
The p.Arg63Trp polymorphism controls Vav1 functions and Foxp3 regulatory T cell development Céline Colacios,Audrey Casemayou,Anne Dejean,Frédérique Gaits-Iacovoni,Christophe Pedroset al. Journal of Experimental Medicine, 2011, 208 (11), pp.2183-2191. ⟨10.1084/jem.20102191⟩ Article dans une revue inserm-04284249v1
The rat Toxo1 locus directs toxoplasmosis outcome and controls parasite proliferation and spreading by macrophage-dependent mechanisms. Pierre Cavaillès,Véronique Sergent,Cordelia Bisanz,Olivier Papapietro,Céline Colacioset al. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103 (3), pp.744-9. ⟨10.1073/pnas.0506643103⟩ Article dans une revue hal-00171244v1
[The rat Toxo1 locus controls the outcome of the toxoplasmic infection according to a mendelian mode] Pierre Cavaillès,Cordelia Bisanz,Olivier Papapietro,Céline Colacios,Véronique Sergentet al. Médecine/Sciences, 2006, 22 (8-9), pp.679-80 Article dans une revue hal-00171242v1

Communication dans un congrès (8)

Targeting ceramide metabolism in melanoma to improve the efficacy of immune checkpoint inhibitor therapy: from basic mechanisms to the clinic. Bruno Ségui,Carine Dufau,Benjamin Jung,Matthieu Genais,Thierry Levadeet al. XV SPHINGOLIPID CLUB MEETING, Sep 2024, Erlangen-Nürnberg, Germany Communication dans un congrès hal-04974692v1
Triple combination of anti-CTLA-4, anti-PD-1 and anti-TNF in mouse melanoma models and advanced melanoma patients. Bruno Ségui,Anne Montfort,Mathieu Virazels,Matthieu Genais,Amélie Lusqueet al. EACR conferences “Defence is the Best Attack: Immuno-Oncology Breakthroughs”, Joan Seoane, May 2023, Barcelona, Spain Communication dans un congrès hal-04974544v1
Sphingolipid metabolism in cancer immune surveillance Céline Colacios The Lysophospholipid and Related Mediators Conference: From Bench to Clinic, FASEB, Jul 2021, Distanciel, France Communication dans un congrès hal-04993184v1
Combining TNF inhibitors to anti-PD-1 and anti-CTLA-4 for the treatment of advanced melanoma patients Anne Montfort,Mathieu Virazels,Carine Dufau,Stéphanie Brayer,Nathalie Andrieu-Abadieet al. 17ème journées du Cancéropôle Grand Sud-Ouest, Nov 2021, Carcassone, France Communication dans un congrès hal-04970934v1
Neutral sphingomyelinase 2 heightens anti-melanoma immune response and synergizes with anti-PD-1. Anne Montfort,Florie Bertrand,Julia Rochotte,Nathalie Andrieu-Abadie,Thierry Levadeet al. Toulouse Oncoweek, Feb 2020, Toulouse, France Communication dans un congrès hal-04971026v1
Ceramide metabolism in melanoma: from basic mechanisms to immunotherapy in advanced melanoma patients. Bruno Ségui,Anne Montfort,Caroline Imbert,Céline Colacios,Nathalie Andrieu-Abadieet al. FEBS 2019 Sphingolipid Biology: Sphingolipids in Physiology and Pathology, Giovanni D'Angelo, Christopher J. Clarke, Liana C. Silva, May 2019, Cascais, Portugal Communication dans un congrès hal-04974329v1
Resistance of Melanoma to Immune Checkpoint Inhibitors is Overcome by Targeting the Sphingosine Kinase 1 Céline Colacios,Caroline Imbert,Anne Montfort,Marine Fraisse,Elie Marcheteauet al. Canceropole GSO, Canceropole GSO, Nov 2019, Arcachon, France Communication dans un congrès hal-04993281v1
Combining TNF-targeting antibodies to immune checkpoint inhibitors in melanoma Anne Montfort,Florie Bertrand,Elie Marcheteau,Caroline Imbert,Julia Gilhodeset al. Toulouse Oncoweek, Feb 2018, Toulouse, France Communication dans un congrès hal-04970883v1

Poster de conférence (6)

Evaluation of the biodistribution of different anti-TNF agents in combination with Immunotherapy in Melanoma model using ImmunoTEP Céline Colacios,Laure Badier,Carine Pestourie,Bruno Ségui,Isabelle Quelven Toulouse Onco Week (TOW) Symposium, Feb 2025, Toulouse, France. Poster de conférence inserm-04973597v1
TNF plasma levels in advanced melanoma patients treated with immune checkpoint inhibitors: results from the MELANFα clinical study. Mathieu Virazels,Amélie Lusque,Thomas Filleron,Clara-Maria Scarlata,Maha Ayyoubet al. Defence is the Best Attack: Immuno-Oncology Breakthroughs, May 2023, Barcelona, France Poster de conférence hal-04971045v1
Triple combination of ipilimumab + nivolumab + anti-TNF in treatment naive melanoma patients: Final analysis of TICIMEL, a phase Ib prospective clinical trial Bruno Ségui,Nicolas Meyer,Amélie Lusque,Mathieu Virazels,Thomas Filleronet al. ESMO congress 2022, Sep 2022, Paris, France. Annals of Oncology, 33 (suppl_7), pp.S936-S937, 2022, ⟨10.1016/j.annonc.2022.07.972⟩ Poster de conférence hal-04975541v1
TNF plasma levels in advanced melanoma patients treated with immune checkpoint inhibitors: results from the MELANFα clinical study. Mathieu Virazels,Anne Montfort,Amélie Lusque,Thomas Filleron,Céline Colacioset al. ESMO Congress 2022, Sep 2022, Paris, France Poster de conférence hal-04971055v1
Combining TNF blockade with immune checkpoint inhibitors in advanced melanoma patients Mathieu Virazels,Anne Montfort,Thomas Filleron,Carine Dufau,Maha Ayyoubet al. 53rd congress of the French Society of Immunology, Dec 2021, Paris, France Poster de conférence hal-04970987v1
Neutral sphingomyelinase 2 heightens anti-melanoma immune response and synergizes with immune checkpoint inhibitors. Anne Montfort,Florie Bertrand,Julia Rochotte,Nathalie Andrieu-Abadie,Thierry Levadeet al. 52ème Congrès de la Société Française d'immunologie (SFI), Nov 2019, Nantes, France Poster de conférence hal-04970950v1

Brevet (2)

Use of sk1 as biomarker for predicting response to immune checkpoint inhibitors. Nathalie Andrieu-Abadie,Nicolas Meyer,Bruno Ségui,Celine Colacios,Thierry Levadeet al. France, Patent n° : WO2019162325A1. 2019 Brevet inserm-04976375v1
Methods for predicting the survival of patients suffering from melanoma. Nathalie Andrieu-Abadie,Nicolas Meyer,Bruno Ségui,Celine Colacios,Joëlle Riondet al. France, Patent n° : WO2020193746A1. 2019 Brevet inserm-04976387v1

HDR (1)

Rôle du TNF et du métabolisme des sphingolipides dans l’immunoéchappement des cancers et l’immunothérapie Céline Colacios Immunologie. Université Paul Sabatier (Toulouse 3), 2022 HDR tel-04993289v1